Product Center
The first phase of the vaccine industrialization project was successfully completed
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2017-08-30
- Views:
(Summary description)The human vaccine industrialization project of Ab&B Bio-Tech CO.,LTD.JS. covers an area of 70 mu, with a planned construction area of 50,000 square meters. The first-phase construction projects include: R&D complex building, production workshop 1, animal room, and central laboratory. The single building, with a total of 30,000 square meters, was successfully completed on August 30, 2017, and then entered the stage of decoration and process construction to prepare for clinical trials in 2018.
The first phase of the vaccine industrialization project was successfully completed
(Summary description)The human vaccine industrialization project of Ab&B Bio-Tech CO.,LTD.JS. covers an area of 70 mu, with a planned construction area of 50,000 square meters. The first-phase construction projects include: R&D complex building, production workshop 1, animal room, and central laboratory. The single building, with a total of 30,000 square meters, was successfully completed on August 30, 2017, and then entered the stage of decoration and process construction to prepare for clinical trials in 2018.
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2017-08-30 10:57
- Views:
The human vaccine industrialization project of Ab&B Bio-Tech CO.,LTD.JS. covers an area of 70 mu, with a planned construction area of 50,000 square meters. The first-phase construction projects include: R&D complex building, production workshop 1, animal room, and central laboratory. The single building, with a total of 30,000 square meters, was successfully completed on August 30, 2017, and then entered the stage of decoration and process construction to prepare for clinical trials in 2018.
Relevant information
-
Ab&B Bio and Yither Bio have both obtained qualification certification!Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) have been recognized as Jiangsu Province's specialized and innovative small and medium-sized enterprises and national high-tech enterprises, respectively. - The kickoff meeting for clinical research on the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome was successfully held 12-25
- Influenza virus subunit vaccine (adjuvant) IND application approved 10-30
- The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
